Citi Raises Price Target on Novo Nordisk Amid Strong Wegovy Pill Launch

Citi has raised its price target for Novo Nordisk (NVO) to DKK330, citing strong performance from the launch of its GLP-1 obesity drug Wegovy. The firm also increased sales and earnings forecasts due to improved growth expectations.

By Proactive Mon, July 20, 2026 at 4:22 PM GMT+3 1 min read · Yahoo Finance · July 20, 2026, 13:22 UTC

Citi Raises Price Target on Novo Nordisk Amid Strong Wegovy Pill Launch

Tickers: $C $NVO

Topics: GLP-1 Drugs Pharmaceuticals Wegovy Launch

Read the full article at Yahoo Finance

More World news

Senate Minority Leader Schumer Demands Congressional Testimony from Nvidia Following Jensen Huang's Resignation The Verge · November 12, 2026, 18:59 UTC
Nvidia Shares Plunge Following CEO Jensen Huang's Departure Amid Investigation Motley Fool · November 12, 2026, 19:00 UTC
San Francisco Fed President Mary Daly Views AI as Transformative Investment Opportunity Seeking Alpha · November 12, 2026, 19:00 UTC
Jensen Huang Resigns as Nvidia CEO Amid Personal Conduct Controversies and China Export Investigations Motley Fool · November 12, 2026, 18:56 UTC
The Adecco Group Reports Q3 2026 Growth Driven by Temporary Staffing and Margin Expansion PR Newswire · November 12, 2026, 18:54 UTC
Twist Bioscience Projects FY2027 Revenue Between $550M and $560M Seeking Alpha · November 12, 2026, 18:50 UTC
Dixie Group Reports Q3 Sales Growth Amid Margin Pressure and Future Cost-Reduction Targets Seeking Alpha · November 12, 2026, 18:50 UTC
Data I/O Corporation Targets Rapid V-TEK Synergy Realization Amid $80 Million M&A Pipeline Seeking Alpha · November 12, 2026, 18:50 UTC
Leatt Corporation Reports 43% Increase in Q3 Revenue to $20.46 Million Seeking Alpha · November 12, 2026, 18:50 UTC
Parsons Reports Strong Third Quarter Results Driven by High-Margin Product Shift Motley Fool · November 12, 2026, 18:45 UTC